BiomeBank
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Ann Nelson Dr, Thebarton, South Austra...Phone Number
+61 872230075Website
www.biomebank.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BiomeBank
BiomeBank is a clinical stage biotechnology company focused on restoring gut microbial ecology to treat diseases and improve health outcomes. They are pioneering next-generation microbiome therapeutics, including co-cultured microbial products designed to address various health challenges such as ulcerative colitis. With a strategic partnership with Blackmores, BiomeBank aims to expand the reach of their innovative probiotics globally. Their flagship product, BIOMICTRA, is the world's first regulated donor-derived therapy for recurrent infections, showcasing their commitment to advancing microbiome medicine.Explore more
BiomeBank Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BiomeBank your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at BiomeBank
Earning: See what the market has to say on BiomeBank recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when BiomeBank launches new products
Click to see if BiomeBank had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BiomeBank has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BiomeBank has recently received funding, and reach out quickly before it becomes old news!
BiomeBank, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if BiomeBank is spiking on competitors!
Recommended Actions
Find VP level buyers at BiomeBank
Find 2 more new buyers
Compare Similar Companies to BiomeBank
Compare insights from companies similar to BiomeBank, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BiomeBank is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BiomeBank is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BiomeBank.
BiomeBank financials insights
Gather financial insights about BiomeBank, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$10.7M
BiomeBank Tech Stack
A closer look at the technologies used by BiomeBank
Most Recent Scoops
New Hire
Executive Move
BiomeBank has announced that Kolby Day has joined the organization as Chief Operating Officer.
Funding
Left Company
Executive Move
New Hire
Executive Move
BiomeBank News & Media
BiomeBank Continues Growth Trajectory With Over $10M Capital Raise
ADELAIDE, Australia--(BUSINESS WIRE)--BiomeBank today announced the successful capital raise of $10 million following the biotechnology company’s world first regulatory approval of its donor derived microbiome drug product. The funding will allow the biotechnology company to scale its GMP manufacturing facility increasing global supply of its recently approved donor derived microbiome-based therapy and further develop its second-generation therapies. The additional capital will support the compBiomeBank Announces World First Regulatory Approval for Donor Derived Microbiome Drug
ADELAIDE, Australia--(BUSINESS WIRE)--BiomeBank today announced the first regulatory approval for a donor derived microbiome drug product worldwide. The Therapeutic Goods Administration (TGA) approved BiomeBank’s product for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection (C.difficile). C.difficile infection is the most common cause of health care associated diarrhoea, a debilitating condition with significant global unmet medical need. BiomeBank'sMicrobiome Medicine Accelerated by New Partnership Between BiomeBank and Hudson Institute
ADELAIDE, Australia--(BUSINESS WIRE)--The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company. A Memorandum of Understanding between the two organisations has been signed, enabling BiomeBank to bring its experience in the discovery and development of microbial therapies to enable translationBiomeBank Appoints Ex-Ellerston Capital CIO and BlackRock North Asia Director ... - Yahoo Finance
ADELAIDE, Australia, January 19, 2022--BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital. Prior to this, Mr Hall served as Managing Director of Blackrock Asset Management (North-Asia Ltd). The appointment is effective as of 17 January 2022.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BiomeBank
Sign Up For FreeTo access detailed company insights
BiomeBank is a clinical stage biotechnology company focused on restoring gut microbial ecology to treat diseases and improve health outcomes. They are pioneering next-generation microbiome therapeutics, including co-cultured microbial products designed to address various health challenges such as ulcerative colitis. With a strategic partnership wit... Read More
